

Premature termination of a Clinical Trial

Full title of the clinical Trial: AMBRISENTAN FOR TREATMENT OF PORTOPULMONARY HYPERTENSION (POPH): A PILOT STUDY

EudraCT Number: 2011-001139-22

Sponsor: Medical University of Graz

Represented by (name): Univ.-Prof. Dr. Rudolf Stauber

Reason for premature termination of the clinical trial:

Screening of 205 patients with portal hypertension revealed POPH in only 3 patients. Two of these 3 patients was treated with ambrisentan outside the study.

Study results (if available):

Douschan P, Kovacs G, Sassmann T, Stadlbauer V, Avian A, Foris V, Tatscher E, Durchschein F, Rainer F, Spindelboeck W, Wagner M, Kniepeiss D, Zollner G, Bachmaier G, Fickert P, Olschewski H, Stauber RE. Pulmonary vascular disease and exercise hemodynamics in chronic liver disease. *Respir Med.* 2022 Oct;202:106987. doi: 10.1016/j.rmed.2022.106987. Epub 2022 Sep 12. PMID: 36115317.

Date and Signature of Sponsor representative:

17 - FEB - 2023

